Haemonetics Co. (NYSE:HAE) EVP Josep Llorens Sells 822 Shares

Haemonetics Co. (NYSE:HAE) EVP Josep Llorens sold 822 shares of Haemonetics stock in a transaction dated Friday, May 17th. The stock was sold at an average price of $94.82, for a total transaction of $77,942.04. Following the completion of the transaction, the executive vice president now owns 16,350 shares of the company’s stock, valued at approximately $1,550,307. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link.

Josep Llorens also recently made the following trade(s):

• On Monday, May 20th, Josep Llorens sold 987 shares of Haemonetics stock. The stock was sold at an average price of $95.08, for a total transaction of $93,843.96.

Haemonetics Price Performance

HAE stock opened at $93.20 on Wednesday. The firm has a 50 day moving average of $86.98 and a 200-day moving average of $83.38. The company has a current ratio of 2.56, a quick ratio of 1.50 and a debt-to-equity ratio of 0.83. Haemonetics Co. has a 12 month low of $70.74 and a 12 month high of $97.97. The firm has a market capitalization of $4.73 billion, a P/E ratio of 40.70, a price-to-earnings-growth ratio of 1.73 and a beta of 0.34.

Haemonetics (NYSE:HAE) last announced its earnings results on Thursday, May 9th. The medical instruments supplier reported $0.90 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.88 by $0.02. Haemonetics had a net margin of 8.98% and a return on equity of 22.25%. The business had revenue of $343.00 million during the quarter, compared to analyst estimates of $329.53 million. During the same period in the previous year, the business posted $0.77 earnings per share. Haemonetics’s revenue for the quarter was up 12.7% on a year-over-year basis. As a group, sell-side analysts predict that Haemonetics Co. will post 4.6 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Haemonetics

Hedge funds and other institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. grew its stake in Haemonetics by 0.5% in the 3rd quarter. Vanguard Group Inc. now owns 5,380,858 shares of the medical instruments supplier’s stock worth $482,017,000 after buying an additional 27,146 shares in the last quarter. Kingdon Capital Management L.L.C. purchased a new position in Haemonetics in the 3rd quarter worth approximately $9,952,000. Lazard Asset Management LLC grew its stake in Haemonetics by 114.2% in the 3rd quarter. Lazard Asset Management LLC now owns 38,538 shares of the medical instruments supplier’s stock worth $3,452,000 after buying an additional 20,550 shares in the last quarter. Los Angeles Capital Management LLC grew its stake in Haemonetics by 1.1% in the 3rd quarter. Los Angeles Capital Management LLC now owns 53,058 shares of the medical instruments supplier’s stock worth $4,753,000 after buying an additional 586 shares in the last quarter. Finally, Eagle Asset Management Inc. boosted its stake in shares of Haemonetics by 2.6% in the 3rd quarter. Eagle Asset Management Inc. now owns 268,643 shares of the medical instruments supplier’s stock valued at $24,065,000 after purchasing an additional 6,828 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company’s stock.

Analyst Upgrades and Downgrades

HAE has been the subject of several recent research reports. Needham & Company LLC reiterated a “hold” rating on shares of Haemonetics in a research note on Friday, May 10th. StockNews.com downgraded shares of Haemonetics from a “buy” rating to a “hold” rating in a research note on Friday, March 22nd. Barrington Research lifted their target price on shares of Haemonetics from $105.00 to $107.00 and gave the stock an “outperform” rating in a research note on Friday, May 10th. TheStreet lowered shares of Haemonetics from a “b-” rating to a “c+” rating in a research report on Thursday, February 29th. Finally, JMP Securities raised their price objective on shares of Haemonetics from $115.00 to $125.00 and gave the company a “market outperform” rating in a research report on Friday, May 10th. Three analysts have rated the stock with a hold rating and two have assigned a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $108.67.

Haemonetics Company Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and intravenous solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system, and Donor360.